| (0.18) | 0.58% |
| SLXP Salix Pharmaceuticals Ltd. | Trade It Now | | NASDAQ |
| |
Market Cap 1.598B Book Value 7.093 EBITDA -27.2M Year Low 7.33 Year High 32.03 PEG Ratio 8.06 EPS -0.884 P/B Ratio 4.35 Short Ratio 3.30 Index Membership S&P 600 SmallCap S&P  Sector Healthcare Industry Drug Related Products Open 30.74 High 30.80 Low 30.30 Last Close 30.82 Volume 854.2 K Target Price 41.33 Current EPS -0.884 This Year EPS 0.09 Next Year EPS 1.46 This Year PE 342.44 Next Year PE 21.11 Salix Pharmaceuticals Ltd.1700 Perimeter Park Drive Morrisville,
NC 27560-8404 United States - Map
Phone: 919-862-1000
Fax: 919-862-1095
Web Site: VisitType: Stock | | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars—Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-14 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-03-16 |  | |
|
Community Discussions | | | 0.22 | 0.69% |
| USNA USANA Health Sciences Inc. | Trade It Now | | NASDAQ |
| |
Market Cap 497.2M Book Value 4.78 EBITDA 57.9M Year Low 19.95 Year High 37.19 PEG Ratio 0.70 EPS 2.174 P/E 14.60 P/B Ratio 6.64 Short Ratio 22.00 Sector Healthcare Industry Drug Related Products Open 31.55 High 32.69 Low 30.85 Last Close 31.74 Volume 58.6 K Target Price 38.20 Current EPS 2.174 This Year EPS 2.50 Next Year EPS 2.84 Current PE 14.60 This Year PE 12.70 Next Year PE 11.18 USANA Health Sciences Inc.3838 West Parkway Boulevard Salt Lake City,
UT 84120 United States - Map
Phone: 801-954-7100
Fax: 801-954-7300
Web Site: VisitType: Stock | | USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. |
Company Summary more  USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. The company offers two product lines, USANA Nutritionals and Sense. The USANA Nutritionals product line consists of essentials, which include vitamin and mineral supplements that provide a foundation of nutrition for various age groups; optimizers, which are targeted supplements that support cardiovascular health, skeletal/structural health, and digestive health; and macro-optimizers comprising low-glycemic functional foods and other related products. The Sense product line includes personal care products that support healthy skin and hair. Products in this line consist of perfecting essence... USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. The company offers two product lines, USANA Nutritionals and Sense. The USANA Nutritionals product line consists of essentials, which include vitamin and mineral supplements that provide a foundation of nutrition for various age groups; optimizers, which are targeted supplements that support cardiovascular health, skeletal/structural health, and digestive health; and macro-optimizers comprising low-glycemic functional foods and other related products. The Sense product line includes personal care products that support healthy skin and hair. Products in this line consist of perfecting essence, gentle daily cleanser, hydrating toner, daytime protective emulsion, eye nourisher, night renewal, serum intensive, rice bran polisher, creme masque, revitalizing shampoo, nourishing conditioner, firming body nourisher, energizing shower gel, and intensive hand therapy. USANA Health Sciences also provides resource materials and sales tools, including product brochures and business forms, as well as sells reprints of other commercial publications. The company distributes its products through network marketing in the United States, Canada, Mexico, Australia, New Zealand, Singapore, Malaysia, Hong Kong, Taiwan, Japan, South Korea, the United Kingdom, and the Netherlands. USANA Health Sciences was founded in 1992 and is headquartered in Salt Lake City, Utah. USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. The company offers two product lines, USANA Nutritionals and Sense. The USANA Nutritionals product line consists of essentials, which include vitamin and mineral supplements that provide a foundation of nutrition for various age groups; optimizers, which are targeted supplements that support cardiovascular health, skeletal/structural health, and digestive health; and macro-optimizers comprising low-glycemic functional foods and other related products. The Sense product line includes personal care products that support healthy skin and hair. Products in this line consist of perfecting essence... Top Stories| | 2010-03-15 |  | |
| | | 2010-03-03 |  | |
| | | 2010-02-19 |  | |
| | |
Usana Health Sciences Q4 net income increases
OptoIQ: Lasers for Manufacturing - Feb 11, 2010
Usana Health Sciences, a developer of nutritional, personal care, and weight management products, has reported a net income of $10.21 million, or $0.66 per diluted share, for the fourth quarter ...
2010-02-11 |  | |
|
Community Discussions |